Improving Prognosis of Progression Risk in Multiple Myeloma Precursors through Single Cell Sequencing-Based Genomic and Immune Microenvironment Profiling

By

The accurate stratification of multiple myeloma (MM) patients by progression risk, into Monoclonal Gammopathy of Undetermined Significance (MGUS) with lower disease burden of 1% progression to MM and Smoldering Myeloma (SMM) with a 10% risk of advancing to MM, remains an urgent clinical need. Basing this stratification on whole genome sequencing (WGS) combined with single … Continued

Comprehensive genomic and immune characterization of response and resistance to daratumumab-based quadruplet induction therapy

By

This study aims to comprehensively characterize the genomic and immune landscape of newly diagnosed multiple myeloma (NDMM) patients treated with daratumumab-based quadruplet induction therapy (dara-quads). Preliminary data suggests that standard prognostic scores are inadequate for predicting outcomes, necessitating the inclusion of complex genomic and immune features. Specific Aim 1 focuses on identifying genomic features associated … Continued

TARGETING METABOLIC SWITCH OF HIGH-RISK MULTIPLE MYELOMA CELLS: TOWARDS THE DESIGN OF AN EXPLORATORY APPROACH FOR AN UNMET CLINICAL NEED

By

Preliminary data suggest that HR landscape promotes metabolic reprogramming to sustain high-proliferation rates accompanied by a higher oxidative state compared with standard risk disease. Given these premises, this project aims to explore the potential benefit of metabolism-targeted therapy in HR-MM patients. For this purpose, we plan: 1) to evaluate multiomics (including genomics, transcriptomics, proteomics) and … Continued

Functional screens on single-cell transcriptomes of genotypically-defined minimal residual disease cells to unravel specific vulnerabilities of treatment resistant multiple myeloma (FUTURE)

By

The research proposed in this grant stems from the hypothesis that phenotypic hierarchies between distinct clonal cells may explain MM ontogeny and relapse patterns, and that through innovative approaches this can be harnessed to provide better biomarkers of treatment response and vulnerabilities to eradicate residual cells. I propose an unbiased simultaneous analysis of B-cell receptor … Continued

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Login
See All of the Member Benefits
Become a Member Today

Stay updated on our Events